Among patients with BM in the HER2− cohort, 39.8% were Stage II and 38.0% were Stage III at initial BC diagnosis; almost half (47.6%) had one metastatic site, and 21.1% had two metastatic sites at initial mBC diagnosis (Table 1; Table S2). The gene discussed is ERBB2; the disease is breast cancer.